Biotech · Private company

Arog Pharmaceuticals, Inc.

Track this companyFree. Adds Arog Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials110 recruiting or active

Pipeline programs32From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline32

CrenolanibPhase 3 · Newly Diagnosed FLT3 Mutated AMLClinicalTrials.gov · fetched Nov 12, 2026
CrenolanibPhase 3 · Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsClinicalTrials.gov · fetched Nov 12, 2026
CrenolanibPhase 3 · GIST With D842V Mutated PDGFRA GeneClinicalTrials.gov · fetched Nov 12, 2026
CytarabinePhase 3 · Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsClinicalTrials.gov · fetched Nov 12, 2026
CytarabinePhase 3 · Newly Diagnosed FLT3 Mutated AMLClinicalTrials.gov · fetched Nov 12, 2026
DuanorubicinPhase 3 · Newly Diagnosed FLT3 Mutated AMLClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 3 · Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsClinicalTrials.gov · fetched Nov 12, 2026
IdarubicinPhase 3 · Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsClinicalTrials.gov · fetched Nov 12, 2026
MidostaurinPhase 3 · Newly Diagnosed FLT3 Mutated AMLClinicalTrials.gov · fetched Nov 12, 2026
MitoxantronePhase 3 · Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsClinicalTrials.gov · fetched Nov 12, 2026
AzacytidinePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
crenolanibPhase 2 · Newly Diagnosed AML With FLT3 Activating MutationsClinicalTrials.gov · fetched Nov 12, 2026
crenolanibPhase 2 · Recurrent/Refractory GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
CrenolanibPhase 2 · Relapsed/Refractory Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
Crenolanib besylatePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Crenolanib besylatePhase 2 · Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior TherapiesClinicalTrials.gov · fetched Nov 12, 2026
Crenolanib Besylate (CP-868,596-26)Phase 2 · Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsClinicalTrials.gov · fetched Nov 12, 2026
cytarabinePhase 2 · Newly Diagnosed AML With FLT3 Activating MutationsClinicalTrials.gov · fetched Nov 12, 2026
CytarabinePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
CytarabinePhase 2 · Relapsed/Refractory Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
daunorubicinPhase 2 · Newly Diagnosed AML With FLT3 Activating MutationsClinicalTrials.gov · fetched Nov 12, 2026
EtoposidePhase 2 · Relapsed/Refractory Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
EtoposidePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 2 · Relapsed/Refractory Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
G-CSFPhase 2 · Relapsed/Refractory Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
idarubicinPhase 2 · Newly Diagnosed AML With FLT3 Activating MutationsClinicalTrials.gov · fetched Nov 12, 2026
IdarubicinPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
MitoxantronePhase 2 · Relapsed/Refractory Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
MitoxantronePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
CrenolanibPhase 1 · Esophagogastric AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
PaclitaxelPhase 1 · Esophagogastric AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
RamucirumabPhase 1 · Esophagogastric AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials11

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AMLPHASE3 · COMPLETED · started Aug 16, 2018ClinicalTrials.gov NCT03250338 · fetched Nov 12, 2026
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AMLPHASE3 · COMPLETED · started Aug 15, 2018ClinicalTrials.gov NCT03258931 · fetched Nov 12, 2026
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric AdenocarcinomaPHASE1 · COMPLETED · started Apr 14, 2017ClinicalTrials.gov NCT03193918 · fetched Nov 12, 2026
Randomized Trial of Crenolanib in Subjects With D842V Mutated GISTPHASE3 · UNKNOWN · started Aug 1, 2016ClinicalTrials.gov NCT02847429 · fetched Nov 12, 2026
Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene AmplificationPHASE2 · COMPLETED · started Apr 1, 2016ClinicalTrials.gov NCT02626364 · fetched Nov 12, 2026
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AMLPHASE1_PHASE2 · COMPLETED · started Feb 1, 2016ClinicalTrials.gov NCT02626338 · fetched Nov 12, 2026
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia PatientsPHASE1_PHASE2 · COMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02400281 · fetched Nov 12, 2026
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia PatientsPHASE2 · COMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02400255 · fetched Nov 12, 2026
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 MutationsPHASE2 · COMPLETED · started Jan 1, 2015ClinicalTrials.gov NCT02283177 · fetched Nov 12, 2026
A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating MutationsPHASE2 · COMPLETED · started Oct 1, 2012ClinicalTrials.gov NCT01657682 · fetched Nov 12, 2026
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating MutationsPHASE2 · COMPLETED · started Jul 1, 2012ClinicalTrials.gov NCT01522469 · fetched Nov 12, 2026